<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164436</url>
  </required_header>
  <id_info>
    <org_study_id>2007-AO0258-45</org_study_id>
    <nct_id>NCT01164436</nct_id>
  </id_info>
  <brief_title>Cohort of HIV Associated Lymphomas</brief_title>
  <acronym>ANRS CO16</acronym>
  <official_title>French Cohort of HIV Associated Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr Yassine Taoufik Dr Houria Chavez Hôpital Bicêtre CIB Paris Sud France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Guislaine Garcelain Hôpital Pitié Slapétrière Paris France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Irène Joab Hôpital Paul Brousse Villejuif France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Alex Duval Fondation Jean Dausset CEPH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Antoine Beclere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of lymphomas is increased among HIV infected patients. In 70 % of cases, those
      are Non Hodgkin's lymphomas (NHL) and Hodgkin lymphomas (HL) in 30% of cases. In France,
      their incidence is estimated to 100 cases per year (data from the &quot;Base de données
      Hospitalière Française sur l'Infection à VIH&quot; (FHDH)). The main mechanisms involved in
      lymphomagenesis are immune dysfunction, involvement of oncogenic viruses (Epstein-Barr (EBV)
      and HHV8) and molecular oncogenic events. A better understanding of these different pathways,
      give the possibility to design specific treatments. The treatment of these lymphomas is not
      standardized. A prospective study of patients with HIV associated lymphoid malignancies is an
      innovating tool to answer epidemiological, physiopathological and therapeutic questions. We
      propose a prospective multicentric study of these patients.

      The main objectives of this prospective study are to:

        -  evaluate the incidence, characterise clinically and histologically NHL and HL cases
           associated to HIV

        -  perform an observational study of the treatment and outcome of these patients out of the
           context of clinical trials,

        -  study the differentiation and activation of B-cell populations,

        -  better understand the role of specific T cell responses in the control of EBV infection,

        -  allow other biological studies from the ANRS group &quot; Lymphome et VIH &quot;.

      The recruitment of 40 cases per year is expected. The length of inclusions is 7 years. The
      follow-up will be of 2 years. Clinical, pathological and biological data at diagnosis and
      during follow-up will be collected. This will allow characterizing the lymphoma, the HIV
      infection, the antitumoral treatments and the outcome of lymphoma. Biological samples will be
      centralized to collect cell, DNA, RNA, plasma, serum and tumour collections (Y.Taoufik, S
      Prevot* ). To better understand the EBV infection and lymphomagenesis in HIV infection, we
      propose to follow the viral load and the molecular characteristics of EBV in PBMC, plasma and
      tumour (P.Morand* , V.Boyer* ), to investigate the EBV-T cell responses (G.Carcelain) and the
      presence and reactivation of EBV in peripheral B cells (C.Amiel* , JC Nicolas) and in tumoral
      samples (M.Raphael* , I.Joab* ). The other mechanisms of lymphomagenesis in HIV infection
      will be studied by the analysis of the sub-populations of B-cells in terms of activation and
      differentiation (Y.Taoufik) and by the characterization of MSI tumours (A.Duval).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between EBV viral load and plasma HIV RNA viral load and CD4 cell count in HIV-infected patients with lymphomas (LNH or LH) at the time of lymphoma diagnosis</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate in HIV patients with NHL or HL</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate in HIV patients with NHL or HL</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of EBV in tumors of HIV patients with NHL or HL</measure>
    <time_frame>5 year</time_frame>
    <description>measurement of EBV using in situ hybridization applied to paraffin sections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of B cell activating cytokines in plasma of HIV patients with NHL or HL</measure>
    <time_frame>5 year</time_frame>
    <description>measurement of concentrations of IL-6, IL-10, BAFF in plasma</description>
  </secondary_outcome>
  <enrollment type="Actual">205</enrollment>
  <condition>HIV Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The recruitment of 80 cases per year is expected. The length of inclusions is 5 years. The
        follow-up will be of 5 years. Clinical, pathological and biological data at diagnosis and
        during follow-up will be collected. This will allow characterizing the lymphoma, the HIV
        infection, the antitumoral treatments and the outcome of lymphoma. Biological samples will
        be centralized to collect cell, DNA, RNA, plasma, serum and tumour collection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients over 18 years of age

          -  patients with HIV-1 or 2 infection

          -  with Non Hodgkin's lymphomas (NHL) or Hodgkin lymphomas (HL) in the diagnosis or in
             relapse

          -  sign an informed consent

        Exclusion Criteria:

          -  patients who suffered from acute leukemia

          -  patients treated for lymphoïd blood disease

          -  Patients whose lymphomas treatment was stopped for less than 3 months

          -  unaffiliated to the social healthy security french system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline BESSON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service Hématologie Immunologie Biologie, Hopital Bicetre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Pialoux, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Tenon Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Caroline Meyonas, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Antoine Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Katlama, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitiè Salpétrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Gabarre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitiè Salpétrière Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Salmon, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cochin PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Dreyfus, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cochin Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Paul Viard, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Devidas, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corbeil Essone 91</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emma Goldschmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Villejuif 94</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecile Goujard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bicêtre 94</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Blum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pointoise 95</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Boué, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clamart 92</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Rosenthal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nice 06</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Burty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vandoeuvre les Nancy 54</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Marie Lang, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strasbourg 67</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renaud Verdon, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Caen 14</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yazdan Yazdanpanah, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tourcoing 59</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Drobacheff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Besancon 25</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Marchou, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse 31</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corinne Couteau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse 31</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Morlat, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bordeaux 33</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Trepo, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lyon 69</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Ghesquières, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lyon 69</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Régis Costellos, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertrand Coiffier, Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pierre Bénite</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude Beuscart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Brieuc 22</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Perre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Roche Sur Yon 85</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Poubeau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Pierre 97</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Raffi, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes 44</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric Lucht, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Etienne 42</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Mounier, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nice 06</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cédric Arvieux, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes 35</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge Herson, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié Salpétrière Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean François Bergmann, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lariboisière Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André Cabié, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fort de France 97( Martinique)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BESSON</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

